Open an account

Rein Therapeutics

RNTX · NASDAQ

$0.5951+$0.0431 (+7.81%)TodayMarket closed ·
Prev close $0.552

RNTX analyst rating

BuyConsensus of 3 analysts over the last 12 months. 67% rate it a buy.
  • Strong buy0
  • Buy2
  • Hold1
  • Underperform0
  • Sell0

12-month price target · 4 analysts

Average $6.12 (+928.4% upside)

Low
$4.04
Now
$0.5951
High
$8.40

Upgrades and downgrades

The latest rating actions, newest first

RNTX analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Aug 18, 2026MaintainsBuy
Maxim GroupJul 20, 2026InitiatesBuy
HC Wainwright & Co.Jun 1, 2026MaintainsBuy
Brookline CapitalJan 21, 2026DowngradeBuy → Hold

The case for and against

Updated Oct 15, 2026

Bull case

Rein Therapeutics is attractive because the company has de-risked its balance sheet with the $57.5M financing, leaving the market focus on execution rather than funding concerns, and the RENEW Phase 2 trial is now funded through completion. Enrollment has surpassed 25% of the planned ~120 patients, is ahead of schedule across all five planned countries, and initial/interim data in 2H26 create a near-term catalyst to test whether LTI-03’s Phase 1b biomarker and epithelial-protection signals translate into meaningful IPF benefit. The fundamental thesis is further strengthened by FDA clearance to resume the program, EMA orphan drug designation, and the company’s broader orphan-pulmonary focus, while 2Q26 results showed a $6.4M net loss, $3.6M R&D expense, and $67.1M weighted-average diluted shares.

Bear case

Rein Therapeutics is viewed negatively because its valuation rests on highly speculative assumptions, including only a 30% probability of success for LTI-03, which reflects early-stage development and historical setbacks in idiopathic pulmonary fibrosis. The company also has a limited cash runway that must be extended to finish the ongoing Phase 2 trial, while 57.5M additional shares from the recent raise signal meaningful dilution and financing dependence. With RNTX trading near $1 and exposed to bid compliance, regulatory, and competitor risks, the profile looks fragile despite its orphan-pulmonary and fibrosis focus.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.